Hepatitis B, Poliomyelitis, Diphtheria, Tetanus, Acellular Pertussis
Conditions
Brief summary
Pre-licensure studies of GSK Biologicals' PEDIARIX vaccine have shown it to be generally safe and unlikely to result in vaccine-associated serious adverse events. This post-licensure study is designed to evaluate relatively uncommon/rare outcomes in a large population cohort.
Detailed description
* The outcomes to be assessed include the occurrence of all seizures (with or without fever), medically-attended fever, seizures associated with fever, allergic reactions, outpatient visits and hospitalizations for any cause, and all deaths. * Data collection through utilization of automated databases at the study site with subset medical record review. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Interventions
BIOLOGICALPediarix
1 or more injections
BIOLOGICALLicensed DTPa containing vaccine
1 or more injections
BIOLOGICALPrevnar®: (Wyeth)
Concomitant vaccination
Sponsors
Kaiser Permanente
University of California, Los Angeles
GlaxoSmithKline
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Weeks to 9 Months
Healthy volunteers
Yes
Inclusion criteria
Primary study cohort The primary study cohort will include all infants from SCKP who have begun their primary course of vaccine with PEDIARIX co-administered with Prevnar and for whom at least one dose of PEDIARIX was administered prior to the infant's 9-month birthday and safety follow-up information is available. Control cohorts Three control cohorts will be evaluated. 1. The historical cohort will include age-, gender- and area-matched infants from SCKP who received at least one dose of DTaP vaccine co-administered with Prevnar prior to the infant's 9-month birthday and for whom safety follow-up information is available. This cohort will include infants vaccinated between January, 2002 and March, 2003. 2. The self-control cohort is defined for the study subject as the 20-day post-vaccination period from Day 21 to Day 41 for each infant in the primary cohort (PEDIARIX co-administered with Prevnar as the primary vaccination course). 3. The delayed PEDIARIX use clinic cohort will include all infants from SCKP who, during the enrollment period for the primary cohort, began their primary course of vaccination with DTaP vaccine and for whom at least one dose of DTaP vaccine was co-administered with Prevnar prior to the infant's 9-month birthday and safety follow-up information is available. The size of this cohort will depend on how quickly individual SCKP clinics and medical centers use PEDIARIX once it is made available. The size of this cohort, therefore, is not immediately predictable.
Exclusion criteria
none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All seizures following the primary doses of PEDIARIX in Cohort A and DTaP vaccine in Cohort B | During the 8-day period following the primary dose |
| Medically-attended fever following the first dose of PEDIARIX in Cohort A and DTaP vaccine in Cohort B | Within 4 days following the first dose |
Secondary
| Measure | Time frame |
|---|---|
| Seizures associated with fever following the primary doses of PEDIARIX or DTaP vaccine | Day 0-3 after 2nd and 3rd doses of PEDIARIX in Cohort A;Day 0-3 after 2nd and 3rd doses of DTaP vaccine in Cohort B;Day 21-41 after primary doses of PEDIARIX in the Cohort A;Day 0-3 after primary doses of DTaP vaccine in the Cohort C |
| Allergic reactions, in cohorts A, B & C | 0 to 48 hours following the primary doses of PEDIARIX or DTaP vaccine |
| Outpatient visits for any cause following the primary doses of PEDIARIX or DTaP vaccine | Day 0-20, Cohort A; Day 0-20, Cohort B; Day 21-41, Cohort A; Day 0-20, Cohort C |
| All seizures following the primary doses of PEDIARIX or DTaP vaccine | Day 21-41, in Cohort A; Day 0-7, in Cohort C |
| Hospitalizations for any cause following PEDIARIX or DTaP vaccine | Day 0 post dose 1 to Day 41 following the last dose and from Day 42 post last dose to 1 year following the last dose |
| Deaths | Day 0 post dose 1 to Day 41 following the last dose and from Day 42 post last dose to 1 year following the last dose |
| Hospitalizations for any cause following the primary doses of PEDIARIX or DTaP vaccine | Day 0-20, Cohort A, Day 0-20, Cohort B; Day 21-41, Cohort A; Day 0-20, Cohort C |
| Medically-attended fever | Day 0-3 after 2nd and 3rd doses of PEDIARIX in Cohort A;Day 0-3 after 2nd and 3rd doses of DTaP vaccine in Cohort B;Day 21-41 after primary doses of PEDIARIX in the Cohort A;Day 0-3 after primary doses of DTaP vaccine in the Cohort C |
Outcome results
None listed